Clinical Implications of the 2004 WHO Histological Classification on Non-Invasive Tumours of the Urinary Bladder{A figure is presented}

EAU-EBU Update Series

Volumn 4, Issue 3-4, 2006, Pages 83-95

  Hofmann, Thomas ^a   Knüchel Clarke, Ruth ^b   Hartmann, Arndt ^c   Stöhr, Robert ^c   Tilki, Derya ^a   Seitz, Michael ^a   Karl, Alexander ^a   Stief, Christian ^a   Zaak, Dirk ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Non invasive urothelial tumours; Progression rate; Recurrence rate; WHO classification

Indexed keywords

ARTICLE; BLADDER PAPILLOMA; BLADDER TUMOR; CANCER GRADING; CARCINOGENESIS; CLINICAL STUDY; CORRELATION ANALYSIS; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TUMOR CLASSIFICATION; TUMOR RECURRENCE; URINARY TRACT TUMOR; UROGENITAL TRACT CANCER; UROGENITAL TRACT TUMOR; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION;

EID: 33744767418     PISSN: 18712592     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eeus.2006.03.002     Document Type: Article

References (57)

1. Mostofi F.K., Sobin L.H., and Torloni H. Histological typing of urinary bladder tumours (1973), World Health Organisation, Geneva
2. Montironi R., Lopez-Beltran A., Mazzucchelli R., and Bostwick D.G. Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol 56 (2003) 91-95
3. Epstein I.J., Amin M.B., Reuter V.R., Mostofi F.K., and the Bladder Consensus Conference Committee. The World Health Organisation/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22 (1998) 1435-1448
4. Sauter G., Algaba F., Amin M., Busch C., Cheville J., Gasser T., et al. Non-Invasive urothelial neoplasias. WHO Classification of non invasive papillary urothelial tumors. In: Eble J.N., Sauter G., Epstein J.I., and Sesterhenn I. (Eds). World Health Organisation classification of tumors. Pathology and genetics: tumors of the urinary system and male genital organs (2004), IARCC Press, Lyon 90-150
5. Hartmann A., Moser K., Kriegmair M., Hofstetter A., Hofstaedter F., and Knuechel R. Frequent genetic alterations in simple urothelial hyperplasia of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154 (1999) 721-727
6. Chow N.H., Cairns P., Eisenberger C.F., Schoenberg M.P., Taylor D.C., Epstein J.I., et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89 (2000) 514-518
7. Obermann E.C., Junker K., Stoehr R., Dietmaier W., Zaak D., Schubert J., et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199 (2003) 50-57
8. Cina S.J., Lancaster-Weiss K.J., Lecksell K., and Epstein J.I. Correlation of Ki-67 and p53 with the new World Health Organisation/International society of Urological Pathology classification system for urothelial neoplasia. Arch Pathol Lab Med 125 (2001) 646-651
9. Taylor D.C., Bhagavan B.S., Larsen M.P., Cox J.A., and Epstein J.I. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am J Surg Pathol 20 (1996) 1481-1488
10. Lopez-Beltran A., Cheng L., Andersson L., Brausi M., de Matteis A., Montironi R., et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update on the Ancona International Consultation. Virchows Arch 440 (2002) 3-11
11. Zaak D., Hungerhuber E., Schneede P., Stepp H., Frimberger D., Corvin S., et al. Role of 5-aminolaevulinic acid in the detection of urothelial premalignant lesions. Cancer 95 (2002) 1234-1238
12. Swierczinsky S.L., and Epstein J.I. Prognostic significance of atypical urothelial hyperplasia. Hum Pathol 33 (2002) 512-517
13. Helpap B., and Köllermann J. Assessment of basal cell status and proliferative patterns in flat and papillary lesions: a contribution to the new WHO classification of urothelial tumors of the urinary bladder. Hum Pathol 31 (2000) 745-750
14. Lakshmi K.P., Cheryl T.L., Montie J., and Shah R.B. Utility of cytokeratin 20 an and Ki-67 as markers of urothelial dysplasia. Pathol Int 55 (2005) 248-254
15. Amin M.B., and McKenney J.K. An Approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/International Society of Urological Pathology consensus classification system. Adv Anat Pathol 9 (2002) 222-232
16. Cheng L., Cheville J.C., Neumann R.M., and Bostwick D.G. Flat intraepithelial lesions of the urinary bladder. Cancer 88 (2000) 625-631
17. Zuk R.J., Rogers H.S., Matin J.E., and Baithun S.I. Clinicopathological importance of primary dysplasia of the bladder. J Clin Pathol 41 (1988) 1277-1280
18. Kiemeney L.M.A., Witjes J.A., Heijbroek R.P., Debruyne F.J.M., and Verbeek A.L.M. Dysplasia in normal-looking urothelium increases the risk of tumor progression in primary superficial cancer. Eur J Cancer 30A (1994) 1621-1625
19. Cheng L., Cheville J.C., Neumann R.M., and Bostwick D.G. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 23 (1999) 443-447
20. Hartmann A., Schlake G., Zaak D., Hungerhuber E., Hofstetter A., Hofstaedter F., et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 62 (2002) 809-818
21. van der Meijden P.M., Sylvester R., Oosterlinck W., Solsona E., Boehle A., Lobel B., et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48 (2005) 363-371
22. Cheng L., Cheville J.C., Neumann R.M., Leibovich B.C., Egan K.S., Spotts B.E., et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 85 (1999) 2469-2474
23. Hudson M.A., and Herr H.W. Carcinoma in situ of the bladder. J Urol 153 (1995) 564-572
24. Hassan J.M., Cookson M.S., Smith J.A., Johnson D.L., and Chang S.S. Outcomes in patient with pathological carcinoma in situ only disease at radical cystectomy. J Urol 172 (2004) 882-884
25. Witjes J.A. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45 (2004) 142-146
26. Dryskjot L., Kruhoffer M., Thykjaer T., Marcussen N., Jensen J.L., Moller K., et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64 (2004) 4040-4048
27. Billerey C., Chopin D., Aubriot-Lorton M.H., Ricol D., de Medina S.G.D., van Rhijn B., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158 (2001) 1955-1959
28. Oosterhuis J.W.A., Schapers R.F.M., Janssen-Heijnen M.L.G., Pauwels R.P.E., Newling D.W., and ten Kate F. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system with conventional grading systems. J Clin Pathol 55 (2002) 900-905
29. Harnden P., Mahmood N., and Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 353 (1999) 974-977
30. Desai S., Dug Lim S., Jimenez R., Chun T., Keane T.E., McKenney J.K., et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 13 (2000) 1315-1323
31. Samaratunga H., Makarov D.V., and Epstein J.I. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 60 (2002) 315-319
32. Cheng L., Darson M., Cheville J.C., Neumann R.M., Zincke H., Nehra A., et al. Urothelial papilloma of the bladder. Clinical and biological implications. Cancer 86 (1999) 2098-2101
33. McKenney J.K., Amin M.B., and Young R.H. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol 16 (2003) 623-629
34. Magi-Galuzzi C., and Epstein J.I. Urothelial papilloma of the bladder. A review of 34 de novo cases. Am J Surg Pathol 28 (2004) 1615-1620
35. van Rhijn B.W.G., Montironi R., Zwarthoff E.C., Jöbsis A., and van der Kwast T.H. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198 (2002) 245-251
36. Witjes J.A., van Blaken M.R., and van de Kaa C.A. The prognostic value of a primary inverted papilloma of the urinary tract. J Urol 158 (1997) 1500-1505
37. Cheville J.C., Wu K., Sebo T.J., Cheng L., Riehle D., Lohse C.M., et al. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?. Cancer 88 (2000) 632-636
38. Broussard J.N., Hoon Tan P., and Epstein J.I. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol 35 (2004) 1499-1504
39. Holmäng S., Andius P., Hedelin H., Wester K., Busch C., and Johannson S.L. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 165 (2001) 1124-1130
40. Campbell P.A., Conrad R.J., Campbell C.M., Nicol D.L., and MacTaggart P. Papillary urothelial neoplasm of low malignant potential: reliabiltiy of diagnosis and outcome. BJU International 93 (2004) 1228-1231
41. Leblanc B., Duclos A.J., Benard F., Cote J., Valquette L., Paquin J.M., et al. Long term followup of initial Ta Grade 1 transitional cell carcinoma of the baldder. J Urol 162 (1999) 1946-1950
42. Larsson P., Wijkström H., Thorstenson A., Adolfson J., Norming U., Wiklund P., et al. A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 37 (2003) 195-201
43. Holmäng S., and Johannson S.L. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 167 (2002) 1634-1637
44. Alsheikh A., Mohamedali Z., Jones E., Masterson J., and Gilks C.B. Comparison of the WHO/ISUP clasification and cytokeratin 20 expression in predicting the behaviour of low-grade papillary urothelial tumors. Mod Pathol 14 (2001) 267-272
45. Pich A., Chiusa L., Formiconi A., Galliano D., Bortolin P., Comino A., et al. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 95 (2002) 784-790
46. Oosterlinck W., Lobel B., Jakse G., Malmström P.U., Stöckle M., and Sternberg C. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
47. Sylvester R., Oosterlinck W., and van der Meijden A. One immediate instillation of chemotherapy TUR reduces the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of the publshed results of randomized clinical trials. J Urol 171 (2004) 2186-2190
48. Holmäng S., Hedelin H., Anderström C., Holmberg E., Busch C., and Johannson S.L. Recurrence and progression in low grade papillary urothelial tumors. J Urol 162 (1999) 702-707
49. Ramos D., Navarro S., Villamon R., Gil-Salmon M., and Llombart-Bosch A. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer 97 (2003) 1876-1883
50. Wild P.J., Herr A., Wissmann C., Stoehr R., Rosenthal A., Zaak D., et al. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res 11 (2005) 4415-4429
51. Cordon-Cardo C., Cote R.J., and Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol Suppl 205 (2000) 82-93
52. Haukaas S., Daehlin L., Maartmann-Moe H., and Ulvik N.M. The long-term outcome in patients with superficial transitional cell carcinoma of the bladder: a single-institutional experience. BJU Int 83 (1999) 957-963
53. Herr H.W. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15 year outcome. J Urol 163 (2000) 60-62
54. In: Mostofi F.J., Davis C.J., and Sesterhenn IA (Eds). Histological Typing of urinary bladder tumours. In: World Health Organisation international histological classification of tumours (1999), Springer Verlag, Berlin, Heidelberg, New York, Tokio 1-103
55. Cheng L., Neumann R.M., and Bostwick D.G. Papillary urothelial neoplasms of low malignant potential. Clinical and biological implications. Cancer 86 (1999) 2102-2108
56. Alvarez Kindelan J., Lopez Beltran A., and Requena Tapia M.J. Urothelial papillary neoplasms of low malignant potential. Retrospective studies. Actas Urol Esp 24 (2000) 743-748
57. Fujii Y., Kawakami S., Koga F., Nemoto T., and Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU International 92 (2003) 559-562